Literature DB >> 11307058

Brain and other central nervous system tumors: rates, trends, and epidemiology.

J G Gurney1, N Kadan-Lottick.   

Abstract

Reports that central nervous system (CNS) cancer rates are increasing have prompted debate on whether secular trends reflect environmental changes related to etiology or artifacts of case ascertainment. We present the most recent data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program on incidence rates and trends of CNS malignancies, including primary CNS lymphomas, and on survival probability. We discuss the new 2000 standard for adjusting rates; underreporting of CNS tumor rates resulting from the exclusion of nonmalignancies in most cancer registries; and information on CNS tumor risk factors, including concerns related to nonionizing electromagnetic fields and wireless mobile telephones.

Entities:  

Mesh:

Year:  2001        PMID: 11307058     DOI: 10.1097/00001622-200105000-00005

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  54 in total

1.  Population-based survival data for brain tumors in Korea.

Authors:  Kyu-Won Jung; Heon Yoo; Hyun-Joo Kong; Young-Joo Won; Sohee Park; Seung Hoon Lee
Journal:  J Neurooncol       Date:  2012-06-04       Impact factor: 4.130

2.  Low incidence of brain tumors among Ethiopian immigrants in Israel.

Authors:  Lee Yaari; Ora Paltiel; Micha Barchana; Irena Liphshiz; Yigal Shoshan
Journal:  J Neurooncol       Date:  2010-06-08       Impact factor: 4.130

3.  Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.

Authors:  Jeonghee Cho; Sandra Pastorino; Qing Zeng; Xiaoyin Xu; William Johnson; Scott Vandenberg; Roel Verhaak; Andrew D Cherniack; Hideo Watanabe; Amit Dutt; Jihyun Kwon; Ying S Chao; Robert C Onofrio; Derek Chiang; Yuki Yuza; Santosh Kesari; Matthew Meyerson
Journal:  Cancer Res       Date:  2011-10-14       Impact factor: 12.701

4.  Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences.

Authors:  Daniel Ruiz-Sánchez; Irene Iglesias Peinado; Miguel Alaguero-Calero; Alejandro José Sastre-Heres; Benito García Diez; Jaime Peña-Díaz
Journal:  Oncol Lett       Date:  2016-07-15       Impact factor: 2.967

Review 5.  Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.

Authors:  Saro H Armenian; Wendy Landier; Melissa M Hudson; Leslie L Robison; Smita Bhatia
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

6.  Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma.

Authors:  Darnell T Josiah; Dongqin Zhu; Fernanda Dreher; John Olson; Grant McFadden; Hannah Caldas
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

7.  Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.

Authors:  Mairéad G McNamara; Zarnie Lwin; Haiyan Jiang; Caroline Chung; Barbara-Ann Millar; Arjun Sahgal; Normand Laperriere; Warren P Mason
Journal:  J Neurooncol       Date:  2014-01-29       Impact factor: 4.130

8.  Caspase-1 mediates Fas-induced apoptosis and is up-regulated by interferon-gamma in human astrocytoma cells.

Authors:  Chulhee Choi; Eunjoo Jeong; Etty N Benveniste
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors.

Authors:  Elisabetta Benedetti; Renato Galzio; Barbara D'Angelo; Maria Paola Cerù; Annamaria Cimini
Journal:  PPAR Res       Date:  2010-03-17       Impact factor: 4.964

10.  Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-κB.

Authors:  Shan Sun; Qiuwei Wang; An Giang; Cong Cheng; Chia Soo; Cun-Yu Wang; Linda M Liau; Robert Chiu
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.